Skip to main content

Table 2 Change in markers from baseline to final study visit

From: Effects of dietary methionine and cysteine restriction on plasma biomarkers, serum fibroblast growth factor 21, and adipose tissue gene expression in women with overweight or obesity: a double-blind randomized controlled pilot study

Plasma marker β for Met/Cys-low vs. Met/Cys-high p β for Met/Cys-medium vs. Met/Cys-high p
ApoA1 6.16 (− 3.33, 16.6) 0.19 − 4.05 (− 12.4, 5.04) 0.35
ApoB − 7.21 (− 22.4, 11) 0.39 − 3.08 (− 18.3, 15) 0.70
ApoB/A1 − 13.3 (− 28.4, 4.88) 0.13 − 0.9 (− 17.7, 19.3) 0.92
Total cholesterol − 1.7 (− 13.2, 11.4) 0.78 − 4.62 (− 14.8, 6.8) 0.39
LDL − 5.25 (− 21.2, 14) 0.54 − 6.69 (− 21.6, 11.1) 0.41
HDL 2.64 (− 5.26, 11.2) 0.50 − 0.68 (− 8.07, 7.3) 0.85
Triglycerides 8.51 (− 24, 55) 0.63 − 4.54 (− 31.7, 33.4) 0.77
C-peptide − 1.2 (− 19.5, 21.2) 0.90 − 4.19 (− 21.2, 16.5) 0.65
Insulin − 19.4 (− 45.6, 19.6) 0.26 − 10.8 (− 38.1, 28.6) 0.52
Glucose 0.48 (− 5.3, 6.61) 0.87 − 0.73 (− 6.26, 5.13) 0.79
SCD16a − 12 (− 27.8, 7.37) 0.19 − 15.7 (− 30.9, 2.84) 0.087
SCD18a 7.16 (− 4.46, 20.2) 0.22 5.98 (− 5.02, 18.3) 0.28
HOMA-IRb − 21.3 (− 47.8, 18.7) 0.23 − 10.3 (− 38.7, 31.2) 0.55
Body weight − 0.29 (− 1.63, 1.08) 0.66 − 0.48 (1.70–0.75) 0.42
  1. Estimated marginal mean change in markers from baseline to the final study visit. Because all raw data values were log-transformed prior to analysis, the βs are given in units of per cent with corresponding confidence intervals
  2. Met/Cys methionine and cysteine, apoA1 apolipoprotein A1, apoB apolipoprotein B, LDL low-density lipoprotein, HDL high-density lipoprotein, SCD stearoyl-CoA desaturase
  3. aSCD16, C16:1n-7/C16:0; SCD18, C18:1n-9/C18:0
  4. bHOMA-IR was calculated by (insulin/6) × (glucose × 18)/405